Home » FDA Clears nContact’s Cardiac Ablation Device

FDA Clears nContact’s Cardiac Ablation Device

January 23, 2013

nContact announced that the FDA has cleared the company’s modifications to its VisiTrax cardiac ablation device, EPi-Sense, now with embedded sensing capability.
BusinessWire

05Aug
Pharmaceutical Quality Risk Management: Navigating the Intersection Between Regulatory Requirements & Risk Management
10Aug
Is Biosimilars Regulation Taking a Major Turn?: The Latest Must-Know Developments, Including BsUFA III
12Aug
On-Site Inspections: They’re Back — But When, Where and How
16Aug
Using AI for CAPA and Root Cause Investigation
28Sep
4th Annual WCG MCC Clinical Trial Risk & Performance Management Collaborative vSummit
12Oct
Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

FDA Clears nContact’s Cardiac Ablation Device

Upcoming Events

Pharmaceutical Quality Risk Management: Navigating the Intersection Between Regulatory Requirements & Risk Management

Is Biosimilars Regulation Taking a Major Turn?: The Latest Must-Know Developments, Including BsUFA III

On-Site Inspections: They’re Back — But When, Where and How

Using AI for CAPA and Root Cause Investigation

4th Annual WCG MCC Clinical Trial Risk & Performance Management Collaborative vSummit

Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

Featured Products

Biological Risk Evaluation and Management for Medical Devices

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

Celltrion Gets Priority Review in Canada for COVID-19 Antibody

Lantheus Gets FDA Clearance for Prostate Cancer Software

FDA Yanks Notice of PDUFA Fee Increase for Fiscal 2022

RealView Imaging’s Medical Holography System Cleared

The Revised ICH E8: A Guide to New Clinical Trial Requirements